Consensus on the appropriate use of intrathecal baclofen (ITB) therapy in paediatric spasticity.

Autor: Dan B; Department of Neurology, Hôpital Universitaire des Enfants Reine Fabiola, Université libre de Bruxelles, 15 Avenue JJ Crocq, 1020 Brussels, Belgium. bernard.dan@ulb.ac.be, Motta F, Vles JS, Vloeberghs M, Becher JG, Eunson P, Gautheron V, Lütjen S, Mall V, Pascual-Pascual SI, Pauwels P, Røste GK
Jazyk: angličtina
Zdroj: European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society [Eur J Paediatr Neurol] 2010 Jan; Vol. 14 (1), pp. 19-28. Date of Electronic Publication: 2009 Jun 21.
DOI: 10.1016/j.ejpn.2009.05.002
Abstrakt: Among features of motor disorders in children, spasticity is associated with considerable morbidity and problems in care, particularly in severely affected patients. Intrathecal baclofen (ITB) has been increasingly used as a relatively specific treatment modality for spasticity. To date, most of the evidence for its use in paediatric patients has come from retrospective and uncontrolled studies, although randomised, controlled trials of screening ITB and ITB therapy itself have recently been published. This consensus statement on the use of ITB in paediatric patients with spasticity was developed on the basis of currently available evidence, with the aim of providing information for clinicians, promoting an expert opinion and a consistent approach to the management of these patients and emphasising the need for further prospective, large-scale studies.
(Copyright 2009. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: